FGFR4 and infectious disease: A dual covalent inhibitor targeting two cysteine residues has recently been described for FGFR4.53 With further optimisation and tailored reactivity of the warhead this strategy provides the potential to develop tools and drug molecules to overcome resistance mutations such as those frequently observed in the infectious disease and oncology areas.